Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.
Joel GarciaStephen Z LiuAngelique Y LouiePublished in: Philosophical transactions. Series A, Mathematical, physical, and engineering sciences (2019)
No discussion of challenges for chemistry in molecular imaging would be complete without addressing the elephant in the room-which is that the purest of chemical compounds needs to interact with a biological system in a manner that does not perturb normal biology while still providing efficacious feedback to assist in diagnosis of disease. In the past decade, magnetic resonance imaging (MRI) agents long considered inert have produced adverse effects in certain patient populations under certain treatment regimens. More recently, inert blood pool agents have been found to deposit in the brain. Release of free metal is often suspected as the culprit but that hypothesis has yet to be validated. In addition, even innocuous agents can cause painful side effects during injection in some patients. In this brief review, we summarize known biological effects for gadolinium- and iron-based MRI contrast agents, and discuss some of the potential mechanisms for the observed biological effects, including the potential role of phosphorus imbalance, related to kidney disease or cancer, in destabilizing gadolinium-based chelates and precipitating free gadolinium.This article is part of the themed issue 'Challenges for chemistry in molecular imaging'.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- diffusion weighted imaging
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- human health
- multiple sclerosis
- case report
- young adults
- brain injury
- squamous cell
- subarachnoid hemorrhage
- climate change